# Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction

Study · id `cardio:ct-nct07362446` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07362446](<https://clinicaltrials.gov/study/NCT07362446>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07362446

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07362446. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-02 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07362446, source copy `cardio:ctgov-nct07362446-2026-11-04`, retrieved 2026-11-18)
- Started: 2026-07-02 (actual) (ClinicalTrials.gov record NCT07362446, source copy `cardio:ctgov-nct07362446-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07362446, source copy `cardio:ctgov-nct07362446-2026-11-04`, retrieved 2026-11-18)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07362446, source copy `cardio:ctgov-nct07362446-2026-11-04`, retrieved 2026-11-18)
- Countries: Australia (ClinicalTrials.gov record NCT07362446, source copy `cardio:ctgov-nct07362446-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07362446-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
- Acronym: PROTECT-MI
- Condition: Myocardial Infarction
- Condition: Reperfusion Injury
- Condition: AMI
- Condition: STEMI (ST Elevation MI)
- Intervention (Drug): Xolatryp
- Intervention (Drug): Placebo
- Lead sponsor: Nyrada Pty Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: 2636d91d38d1f3ba314a81868708ea3f4add9e156c2ae6a3068fe48faf3a395b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
